Attovia Therapeutics grants 538,300 stock options

Attovia Therapeutics, Inc. reported a grant of stock options covering 538,300 shares of common stock with an exercise price of $17.00 per share.

Accepted by SEC EDGAR 08/06/2026 - 05:11 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. reported a grant of stock options covering 538,300 shares of common stock with an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the vesting schedule, 25% vests on August 4, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.

Insider Trade Summary

Grant/Award: 538,300 shares

Grant/Award 1 txn

Insider Attovia Therapeutics, Inc.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	538,300	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 538,300 contracts (Direct)

Footnotes (1)

1. F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

Key Figures

Options granted: 538,300 shares Exercise price: $17.00 per share Underlying shares: 538,300 shares +3 more

6 metrics

Options granted 538,300 shares Stock Option (Right to Buy) award reported in the Form 4

Exercise price $17.00 per share Conversion or exercise price of the stock options

Underlying shares 538,300 shares Common stock underlying the reported stock option grant

Expiration date August 3, 2036 Expiration of the granted stock options

Initial vesting date August 4, 2027 25% of options vest on this date, per footnote

Vesting period for remainder 36 months Remaining 75% vests in equal monthly installments thereafter

Key Terms

Stock Option (Right to Buy), exercise price, vesting, underlying security

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the options shall vest on August 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Attovia Therapeutics (ATTO) report in this Form 4?

Attovia Therapeutics reported a grant of stock options for 538,300 shares of common stock at an exercise price of $17.00 per share, expiring on August 3, 2036, as reflected in the Form 4 filing.

What is the exercise price of the new stock options reported by ATTO?

The newly granted stock options have an exercise price of $17.00 per share. These options relate to 538,300 shares of Attovia Therapeutics common stock and are scheduled to expire on August 3, 2036, subject to the stated vesting conditions.

How many Attovia Therapeutics (ATTO) shares are covered by the reported stock option grant?

The stock option grant covers 538,300 underlying shares of Attovia Therapeutics common stock. All of these shares are tied to a single option award with a $17.00 exercise price and an expiration date of August 3, 2036.

What is the vesting schedule for the Attovia Therapeutics (ATTO) stock options granted?

According to the filing, 25% of the options vest on August 4, 2027, while the remaining 75% vest in equal monthly installments over the following 36 months, contingent on continued service to Attovia Therapeutics.

Are the Attovia Therapeutics (ATTO) options immediately exercisable?

The options are not fully vested immediately. Only after August 4, 2027 does 25% vest, with the remaining 75% vesting in monthly installments over the next 36 months, all subject to continued service to the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Attovia Therapeutics, Inc.

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17	08/04/2026		A		538,300		(1)	08/03/2036	Common Stock	538,300	$0	538,300	D

Explanation of Responses:

1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

	Steven Chan, Attorney-in-Fact for Tao Fu	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)